Lupin completes Phase 3 Trials for Lucentis Biosimilar EP News Bureau Aug 6, 2024 The study has achieved its primary endpoint of therapeutic equivalence in visual acuity improvement for wet AMD patients,…
Enzene Biosciences launches Ranibizumab to treat neovascular AMD EP News Bureau Nov 24, 2023 Ranibizumab biosimilar is the company’s seventh biosimilar
Intas and Axantia sign licence and supply agreement for Ranibizumab biosimilar in Middle East EP News Bureau Apr 5, 2022 Under the terms of this agreement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in…
